128 related articles for article (PubMed ID: 37725566)
1. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
Balakirouchenane D; Seban R; Groussin L; Puszkiel A; Cottereau AS; Clerc J; Vidal M; Goldwasser F; Arrondeau J; Blanchet B; Huillard O
Thyroid; 2023 Nov; 33(11):1327-1338. PubMed ID: 37725566
[No Abstract] [Full Text] [Related]
2. Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.
Balakirouchenane D; Guégan S; Csajka C; Jouinot A; Heidelberger V; Puszkiel A; Zehou O; Khoudour N; Courlet P; Kramkimel N; Lheure C; Franck N; Huillard O; Arrondeau J; Vidal M; Goldwasser F; Maubec E; Dupin N; Aractingi S; Guidi M; Blanchet B
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32283865
[TBL] [Abstract][Full Text] [Related]
3. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
5. Dabrafenib Versus Dabrafenib + Trametinib in
Busaidy NL; Konda B; Wei L; Wirth LJ; Devine C; Daniels GA; DeSouza JA; Poi M; Seligson ND; Cabanillas ME; Sipos JA; Ringel MD; Eisfeld AK; Timmers C; Shah MH
Thyroid; 2022 Oct; 32(10):1184-1192. PubMed ID: 35658604
[No Abstract] [Full Text] [Related]
6. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S; Do Cao C; Zerdoud S; Attard M; Bournaud C; Lacroix L; Benisvy D; Taïeb D; Bardet S; Terroir-Cassou-Mounat M; Anizan N; Bouvier-Morel E; Lamartina L; Lion G; Betrian S; Sajous C; Schiazza A; Garcia ME; Ciappuccini R; Schlumberger M; Al Ghuzlan A; Godbert Y; Borget I
Clin Cancer Res; 2023 Jul; 29(13):2401-2409. PubMed ID: 37074727
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
8. Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
Montes de Jesus FM; Espeli V; Paone G; Giovanella L
Endocrine; 2023 Sep; 81(3):450-454. PubMed ID: 37191938
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
10. Redifferentiation of a
Leboulleux S; Dupuy C; Lacroix L; Attard M; Grimaldi S; Corre R; Ricard M; Nasr S; Berdelou A; Hadoux J; Hartl D; Terroir M; Baudin E; Schlumberger M; Al Ghuzlan A
Thyroid; 2019 May; 29(5):735-742. PubMed ID: 30880598
[TBL] [Abstract][Full Text] [Related]
11. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.
Groenland SL; Janssen JM; Nijenhuis CM; de Vries N; Rosing H; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU; Beijnen JH; Huitema ADR; Steeghs N
Cancer Chemother Pharmacol; 2023 Jun; 91(6):447-456. PubMed ID: 36947208
[TBL] [Abstract][Full Text] [Related]
13. Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
Weber M; Kersting D; Riemann B; Brandenburg T; Führer-Sakel D; Grünwald F; Kreissl MC; Dralle H; Weber F; Schmid KW; Herrmann K; Jentzen W; Grafe H; Rischpler C; Theurer S; Bockisch A; Nagarajah J; Fendler WP
Clin Cancer Res; 2022 Oct; 28(19):4194-4202. PubMed ID: 35594174
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
16. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
17. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
18. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and
Leboulleux S; Benisvy D; Taieb D; Attard M; Bournaud C; Terroir-Cassou-Mounat M; Lacroix L; Anizan N; Schiazza A; Garcia ME; Ghuzlan AA; Lamartina L; Schlumberger M; Godbert Y; Borget I
Thyroid; 2023 Sep; 33(9):1124-1129. PubMed ID: 37350119
[No Abstract] [Full Text] [Related]
19. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
[TBL] [Abstract][Full Text] [Related]
20. Redifferentiating Effect of Larotrectinib in
Groussin L; Theodon H; Bessiene L; Bricaire L; Bonnet-Serrano F; Cochand-Priollet B; Leroy K; Garinet S; Pasmant E; Zerbit J; Seban R; Goldwasser F; Clerc J; Cottereau AS; Huillard O
Thyroid; 2022 May; 32(5):594-598. PubMed ID: 35171708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
